BioCentury | Mar 12, 2020
Management Tracks

Hoerr takes helm from Menichella at CureVac; plus Genmab hires Mancini as COO, Tricida, Akcea, Refuge, Adaptate, Thermo Fisher and more

German mRNA company CureVac AG said founder and Chairman Ingmar Hoerr is replacing Daniel Menichella as CEO. Menichella joined the company as CBO as well as CEO of CureVac’s U.S. subsidiary in January 2017, becoming...
BioCentury | Oct 15, 2019
Tools & Techniques

Yale takes CRISPR beyond editing, turning cold tumors hot

A Yale team has developed a new use for CRISPR as a cancer vaccine that turns cold tumors hot by boosting neoantigen expression, rather than editing genes. In the realm of cancer, CRISPR’s application to...
BioCentury | Feb 21, 2019
Emerging Company Profile

Refuge: Receptive CAR checkpoints

Refuge Biotechnologies Inc. aims to make CAR T cells more potent by suppressing their checkpoint genes and is using a form of CRISPR that knocks the genes down instead of out to improve safety. CEO...
BioCentury | Nov 21, 2018
Politics & Policy

Chinese foothold in U.S. biotech is growing, USTR report finds

Despite recent efforts to crack down on foreign entities gaining access to U.S. IP and innovation through investment, Chinese VC investment in U.S. biotech is increasing, according to a report from the United States Trade...
BioCentury | May 4, 2018
Financial News

Refuge raises $25M series B

Refuge Biotechnologies Inc. (Menlo Park, Calif.) raised $25 million on May 2 in a series B round led by 3SBio Inc. (HKSE:1530) and Sequoia China. Fellow new investors Danhua Capital (DHVC), Sangel Capital and Ocean...
BioCentury | May 2, 2018
Financial News

Refuge raises $25M series B

Refuge Biotechnologies Inc. (Menlo Park, Calif.) raised $25 million in a series B round led by 3SBio Inc. (HKSE:1530) and Sequoia China. Fellow new investors Danhua Capital (DHVC), Sangel Capital and Ocean Pine Healthcare Fund...
Items per page:
1 - 6 of 6
BioCentury | Mar 12, 2020
Management Tracks

Hoerr takes helm from Menichella at CureVac; plus Genmab hires Mancini as COO, Tricida, Akcea, Refuge, Adaptate, Thermo Fisher and more

German mRNA company CureVac AG said founder and Chairman Ingmar Hoerr is replacing Daniel Menichella as CEO. Menichella joined the company as CBO as well as CEO of CureVac’s U.S. subsidiary in January 2017, becoming...
BioCentury | Oct 15, 2019
Tools & Techniques

Yale takes CRISPR beyond editing, turning cold tumors hot

A Yale team has developed a new use for CRISPR as a cancer vaccine that turns cold tumors hot by boosting neoantigen expression, rather than editing genes. In the realm of cancer, CRISPR’s application to...
BioCentury | Feb 21, 2019
Emerging Company Profile

Refuge: Receptive CAR checkpoints

Refuge Biotechnologies Inc. aims to make CAR T cells more potent by suppressing their checkpoint genes and is using a form of CRISPR that knocks the genes down instead of out to improve safety. CEO...
BioCentury | Nov 21, 2018
Politics & Policy

Chinese foothold in U.S. biotech is growing, USTR report finds

Despite recent efforts to crack down on foreign entities gaining access to U.S. IP and innovation through investment, Chinese VC investment in U.S. biotech is increasing, according to a report from the United States Trade...
BioCentury | May 4, 2018
Financial News

Refuge raises $25M series B

Refuge Biotechnologies Inc. (Menlo Park, Calif.) raised $25 million on May 2 in a series B round led by 3SBio Inc. (HKSE:1530) and Sequoia China. Fellow new investors Danhua Capital (DHVC), Sangel Capital and Ocean...
BioCentury | May 2, 2018
Financial News

Refuge raises $25M series B

Refuge Biotechnologies Inc. (Menlo Park, Calif.) raised $25 million in a series B round led by 3SBio Inc. (HKSE:1530) and Sequoia China. Fellow new investors Danhua Capital (DHVC), Sangel Capital and Ocean Pine Healthcare Fund...
Items per page:
1 - 6 of 6